Publications by authors named "L Davidson-Ray"
Background: The VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) demonstrated that, in patients with high-risk heart failure, vericiguat reduced the primary composite outcome of cardiovascular death or heart failure hospitalization relative to placebo. The hazard ratio for all-cause mortality was 0.95 (95% CI, 0.
View Article and Find Full Text PDFDisparities in Loss to Follow-Up Among Adults With Congenital Heart Disease in North Carolina.
World J Pediatr Congenit Heart Surg
November 2022
Article Synopsis
- - The study analyzed follow-up care for adults with congenital heart disease (CHD) in North Carolina, revealing that 39% of patients did not receive the recommended follow-up within two years after their initial healthcare encounter.
- - Among the 2822 patients studied, those with severe CHD had better follow-up rates (72%) compared to those with less severe conditions (55%), while follow-up was notably lower among Black patients (56%) than White patients (64%).
- - Younger age, having non-severe CHD, and being from a minority background were identified as factors that increased the likelihood of inadequate follow-up, suggesting a need for targeted health interventions to improve care retention in these groups.
Background: In the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation), catheter ablation did not significantly reduce the primary end point of death, disabling stroke, serious bleeding, or cardiac arrest compared with drug therapy by intention-to-treat, but did improve the quality of life and freedom from atrial fibrillation recurrence. In the heart failure subgroup, ablation improved both survival and quality of life. Cost-effectiveness was a prespecified CABANA secondary end point.
View Article and Find Full Text PDFBackground In clinical trials, cangrelor has been shown to reduce percutaneous coronary intervention-related ischemic complications without increasing major bleeding. This study was performed to examine cangrelor use and transition to oral P2Y inhibitors in routine clinical practice. Methods and Results The CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry is a multicenter, retrospective observational study of platelet inhibition strategies for patients with myocardial infarction undergoing percutaneous coronary intervention.
View Article and Find Full Text PDFBackground: The STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure) demonstrated that coronary artery bypass grafting (CABG) reduced all-cause mortality rates out to 10 years compared with medical therapy alone (MED) in patients with ischemic cardiomyopathy and reduced left ventricular function (ejection fraction ≤35%). We examined the economic implications of these results.
Methods: We used a decision-analytic patient-level simulation model to estimate the lifetime costs and benefits of CABG and MED using patient-level resource use and clinical data collected in the STICH trial.